Literature DB >> 33384991

Interferon-γ and Hypoxia Priming Have Limited Effect on the miRNA Landscape of Human Mesenchymal Stromal Cells-Derived Extracellular Vesicles.

Juliette Peltzer1,2, Kyle Lund1, Marie-Emmanuelle Goriot1,2, Marion Grosbot1,2, Jean-Jacques Lataillade1,2, Philippe Mauduit2, Sébastien Banzet1,2.   

Abstract

Mesenchymal stromal cell (MSC)-based cell therapy has received great interest in regenerative medicine. Priming the cells during the culture phase can improve their efficacy and/or survival after injection. The literature suggests that MSC extracellular vesicles (EV) can recapitulate a substantial part of the beneficial effects of the cells they originate from, and that micro-RNAs (miRNAs) are important players in EV biological action. Here, our aim was to determine if two classical priming methods of MSC, interferon-gamma (IFNγ) and hypoxia (HYP), could modify their EV miRNA content. Human bone marrow MSCs (BM-MSCs) from five healthy donors were cultured with IFNγ or in HYP or in control (CONT) conditions. The conditioned media were collected after 48 h in serum-free condition and EV were isolated by ultracentrifugation. Total RNA was isolated, pools of CONT, IFN, and HYP cDNA were prepared, and a miRNA profiling was performed using RT-qPCR. Then, miRNAs were selected based on their detectability and measured on each individual EV sample. Priming had no effect on EV amount or size distribution. A set of 81 miRNAs was detected in at least one of the pools of EVs. They were measured on each individual sample; 41 miRNAs were detected in all samples. The principal component analysis (PCA) failed to discriminate the groups. HYP induced a significant decrease in EV hsa-miR-34a-3p content and IFN induced a significant increase in five miRNAs (hsa-miR-25-3p, hsa-miR-106a-5p, hsa-miR-126-3p, hsa-miR-451a, and hsa-miR-665). Taken together, we found only limited alterations in the miRNA landscape of MSC EV with a high inter-individual variability.
Copyright © 2020 Peltzer, Lund, Goriot, Grosbot, Lataillade, Mauduit and Banzet.

Entities:  

Keywords:  exosome (vesicle); extracellular vesicles; mesenchymal stem cells; mesenchymal stromal cells; miRNA; priming

Year:  2020        PMID: 33384991      PMCID: PMC7769832          DOI: 10.3389/fcell.2020.581436

Source DB:  PubMed          Journal:  Front Cell Dev Biol        ISSN: 2296-634X


  55 in total

1.  FunRich: An open access standalone functional enrichment and interaction network analysis tool.

Authors:  Mohashin Pathan; Shivakumar Keerthikumar; Ching-Seng Ang; Lahiru Gangoda; Camelia Y J Quek; Nicholas A Williamson; Dmitri Mouradov; Oliver M Sieber; Richard J Simpson; Agus Salim; Antony Bacic; Andrew F Hill; David A Stroud; Michael T Ryan; Johnson I Agbinya; John M Mariadason; Antony W Burgess; Suresh Mathivanan
Journal:  Proteomics       Date:  2015-06-17       Impact factor: 3.984

2.  Exosomal miR-21a-5p mediates cardioprotection by mesenchymal stem cells.

Authors:  Kristin M Luther; Lauren Haar; Myc McGuinness; Yang Wang; Thomas L Lynch Iv; Anh Phan; Yang Song; Zilong Shen; George Gardner; Gina Kuffel; Xiaoping Ren; Michael J Zilliox; W Keith Jones
Journal:  J Mol Cell Cardiol       Date:  2018-04-23       Impact factor: 5.000

3.  Donor variation in the growth properties and osteogenic potential of human marrow stromal cells.

Authors:  D G Phinney; G Kopen; W Righter; S Webster; N Tremain; D J Prockop
Journal:  J Cell Biochem       Date:  1999-12-01       Impact factor: 4.429

4.  Graft-Versus-Host Disease Amelioration by Human Bone Marrow Mesenchymal Stromal/Stem Cell-Derived Extracellular Vesicles Is Associated with Peripheral Preservation of Naive T Cell Populations.

Authors:  Sumie Fujii; Yasuo Miura; Aya Fujishiro; Takero Shindo; Yutaka Shimazu; Hideyo Hirai; Hidetoshi Tahara; Akifumi Takaori-Kondo; Tatsuo Ichinohe; Taira Maekawa
Journal:  Stem Cells       Date:  2017-12-27       Impact factor: 6.277

5.  Proteomic Analysis and Identification of Paracrine Factors in Mesenchymal Stem Cell-Conditioned Media under Hypoxia.

Authors:  Suk-Won Song; Kyung-Eun Kim; Jung-Won Choi; Chang Youn Lee; Jiyun Lee; Hyang-Hee Seo; Kyu Hee Lim; Soyeon Lim; Seahyong Lee; Sang Woo Kim; Ki-Chul Hwang
Journal:  Cell Physiol Biochem       Date:  2016-11-21

6.  IFN-gamma priming of adipose-derived stromal cells at "physiological" hypoxia.

Authors:  Elena R Andreeva; Olga O Udartseva; Olga V Zhidkova; Sergey V Buravkov; Maria I Ezdakova; Ludmila B Buravkova
Journal:  J Cell Physiol       Date:  2017-08-11       Impact factor: 6.384

7.  Improved survival of mesenchymal stromal cell after hypoxia preconditioning: role of oxidative stress.

Authors:  Karen M Peterson; Abdelrahman Aly; Amir Lerman; Lilach O Lerman; Martin Rodriguez-Porcel
Journal:  Life Sci       Date:  2010-11-06       Impact factor: 5.037

8.  The microRNA regulatory landscape of MSC-derived exosomes: a systems view.

Authors:  Scott W Ferguson; Jinli Wang; Christine J Lee; Maixian Liu; Sriram Neelamegham; John M Canty; Juliane Nguyen
Journal:  Sci Rep       Date:  2018-01-23       Impact factor: 4.379

9.  Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes.

Authors:  Jo Vandesompele; Katleen De Preter; Filip Pattyn; Bruce Poppe; Nadine Van Roy; Anne De Paepe; Frank Speleman
Journal:  Genome Biol       Date:  2002-06-18       Impact factor: 13.583

10.  Safety Profile of Good Manufacturing Practice Manufactured Interferon γ-Primed Mesenchymal Stem/Stromal Cells for Clinical Trials.

Authors:  Adam J Guess; Beth Daneault; Rongzhang Wang; Hillary Bradbury; Krista M D La Perle; James Fitch; Sheri L Hedrick; Elizabeth Hamelberg; Caroline Astbury; Peter White; Kathleen Overolt; Hemalatha Rangarajan; Rolla Abu-Arja; Steven M Devine; Satoru Otsuru; Massimo Dominici; Lynn O'Donnell; Edwin M Horwitz
Journal:  Stem Cells Transl Med       Date:  2017-09-09       Impact factor: 6.940

View more
  7 in total

Review 1.  Preconditioning and Engineering Strategies for Improving the Efficacy of Mesenchymal Stem Cell-Derived Exosomes in Cell-Free Therapy.

Authors:  Shenyuan Chen; Fengtian Sun; Hui Qian; Wenrong Xu; Jiajia Jiang
Journal:  Stem Cells Int       Date:  2022-05-14       Impact factor: 5.131

2.  Priming With Toll-Like Receptor 3 Agonist Poly(I:C) Enhances Content of Innate Immune Defense Proteins but Not MicroRNAs in Human Mesenchymal Stem Cell-Derived Extracellular Vesicles.

Authors:  Lisa M Pierce; Wendy E Kurata
Journal:  Front Cell Dev Biol       Date:  2021-05-24

Review 3.  Harnessing Tissue-derived Extracellular Vesicles for Osteoarthritis Theranostics.

Authors:  Bohan Yin; Junguo Ni; Claire E Witherel; Mo Yang; Jason A Burdick; Chunyi Wen; Siu Hong Dexter Wong
Journal:  Theranostics       Date:  2022-01-01       Impact factor: 11.600

4.  Lung Fibrosis Is Improved by Extracellular Vesicles from IFNγ-Primed Mesenchymal Stromal Cells in Murine Systemic Sclerosis.

Authors:  Pauline Rozier; Marie Maumus; Alexandre Thibault Jacques Maria; Karine Toupet; Christian Jorgensen; Philippe Guilpain; Danièle Noël
Journal:  Cells       Date:  2021-10-13       Impact factor: 6.600

Review 5.  Mesenchymal Stem Cell-Derived Exosomes and MicroRNAs in Cartilage Regeneration: Biogenesis, Efficacy, miRNA Enrichment and Delivery.

Authors:  Jhi Biau Foo; Qi Hao Looi; Chee Wun How; Sau Har Lee; Maimonah Eissa Al-Masawa; Pei Pei Chong; Jia Xian Law
Journal:  Pharmaceuticals (Basel)       Date:  2021-10-28

Review 6.  Enhancement strategies for mesenchymal stem cells and related therapies.

Authors:  Senthilkumar Alagesan; Jack Brady; Declan Byrnes; Juan Fandiño; Claire Masterson; Sean McCarthy; John Laffey; Daniel O'Toole
Journal:  Stem Cell Res Ther       Date:  2022-02-21       Impact factor: 6.832

7.  Joint Tissue Protective and Immune-Modulating miRNA Landscape of Mesenchymal Stromal Cell-Derived Extracellular Vesicles under Different Osteoarthritis-Mimicking Conditions.

Authors:  Enrico Ragni; Carlotta Perucca Orfei; Federico Sinigaglia; Laura de Girolamo
Journal:  Pharmaceutics       Date:  2022-07-02       Impact factor: 6.525

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.